VCYT: Acquisition and innovation drive portfolio growth, with strong test performance and expanding market reach
The event highlighted a strategic acquisition to expand the bladder cancer portfolio, strong growth in Decipher and Afirma tests, and the launch of new products like Prosigna and TrueMRD. Operational synergies, robust evidence generation, and a balanced reinvestment approach underpin a positive fin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.